BiotechTube

Arzoxifene + Placebo

Phase 3Completed
0 views this week 0 watching⚡ Active
Interest: 40/100
40
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
✓
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Postmenopausal Bone Loss

Conditions

Postmenopausal Bone Loss

Trial Timeline

Apr 1, 2004 → Feb 1, 2007

NCT ID
NCT00085956

About Arzoxifene + Placebo

Arzoxifene + Placebo is a phase 3 stage product being developed by Eli Lilly for Postmenopausal Bone Loss. The current trial status is completed. This product is registered under clinical trial identifier NCT00085956. Target conditions include Postmenopausal Bone Loss.

What happened to similar drugs?

20 of 20 similar drugs in Postmenopausal Bone Loss were approved

Approved (20) Terminated (1) Active (0)
✅Teriparatide + Strontium ranelateEli LillyApproved
✅teriparatideEli LillyApproved
✅Teriparatide + RaloxifeneEli LillyApproved
✅teriparatide + aldrenodate + raloxifeneEli LillyApproved
✅teriparatide + raloxifene HCl + placeboEli LillyApproved
✅Teriparatide + Risedronate + Placebo + Calcium + Vitamin DEli LillyApproved
✅LetrozoleNovartisApproved

Hype Score Breakdown

Clinical
17
Activity
8
Company
15
Novelty
0
Community
0

Clinical Trials (3)

NCT IDPhaseStatus
NCT00767299Phase 2Completed
NCT00088010Phase 3Completed
NCT00085956Phase 3Completed

Competing Products

20 competing products in Postmenopausal Bone Loss

See all competitors
ProductCompanyStageHype Score
ENZ215 + ProliaAlkem LaboratoriesPhase 3
40
teriparatide + teriparatide + Placebo + Calcium Supplement + Vitamin D SupplementEli LillyPhase 3
40
teriparatide 20 micrograms/day subcutaneous + salmon calcitonin 100 IU/day subcutaneousEli LillyPhase 3
40
CT-P41 + US-licensed ProliaCelltrionPhase 3
40
LetrozoleChugai PharmaceuticalPhase 2
35
Eldecalcitol soft capsulesChugai PharmaceuticalPre-clinical
22
LetrozoleChugai PharmaceuticalPhase 2
35
LetrozoleChugai PharmaceuticalPhase 2
35
menatetranone + alfacalcidolEisaiPhase 3
40
teriparatide + raloxifene + placeboEli LillyPhase 3
40
Teriparatide + Strontium ranelateEli LillyApproved
43
teriparatideEli LillyApproved
43
LY333334 + PlaceboEli LillyPhase 1
29
Teriparatide + RaloxifeneEli LillyApproved
43
teriparatide + aldrenodate + raloxifeneEli LillyApproved
43
LAE102 SC + Placebo SC + LAE102 IV + Placebo IVEli LillyPhase 1
29
BlosozumabEli LillyPhase 1
29
BlosozumabEli LillyPhase 1
21
Arzoxifene + RaloxifeneEli LillyPhase 3
40
teriparatide + raloxifene HCl + placeboEli LillyApproved
43